Mckesson

McKesson, a US-based pharmaceutical preparation manufacturing company, reported its latest available emissions data for 2025. In 2025, the company's Scope 1 emissions were 72,223,000 kg CO2e, and its Scope 2 market-based emissions were 119,935,000 kg CO2e. Scope 3 emissions for the same year totalled 36,077,096,000 kg CO2e, with significant contributions from purchased goods and services (35,577,078,000 kg CO2e) and upstream transportation and distribution (285,627,000 kg CO2e).

Looking back, in 2024, McKesson's Scope 1 emissions were 79,848,000 kg CO2e, and Scope 2 market-based emissions were 152,129,000 kg CO2e. Scope 3 emissions in 2024 were 32,569,160,000 kg CO2e, primarily driven by purchased goods and services (31,925,992,000 kg CO2e) and upstream transportation and distribution (398,635,000 kg CO2e).

McKesson has set Science Based Targets initiative (SBTi) approved targets to address its climate impact. The company commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 50.4% by fiscal year 2032, using a fiscal year 2020 base year. Furthermore, McKesson aims for 70% of its suppliers by spend, covering purchased goods and services, to have science-based targets by fiscal year 2027.